{"log_id": 801253615945444636, "direction": 0, "words_result_num": 37, "words_result": [{"probability": {"variance": 5e-06, "average": 0.998473, "min": 0.989623}, "location": {"width": 790, "top": 210, "height": 42, "left": 200}, "words": "内假注射(n=63),之后每三月给药一次。从第14个月开始,允许假注射的患者"}, {"probability": {"variance": 0.000263, "average": 0.995676, "min": 0.905237}, "location": {"width": 788, "top": 245, "height": 41, "left": 200}, "words": "改为接受雷珠单抗治疗,从第19个月开始,可能进行更频繁的治疗。在PIER研"}, {"probability": {"variance": 1e-06, "average": 0.999271, "min": 0.995855}, "location": {"width": 433, "top": 286, "height": 33, "left": 200}, "words": "究中,本品治疗的患者平均接受了10次治疗"}, {"probability": {"variance": 1.8e-05, "average": 0.998358, "min": 0.976324}, "location": {"width": 743, "top": 341, "height": 40, "left": 247}, "words": "主要疗效终点为:相对于基线值,治疗第12个月时视力的平均改变。在最初"}, {"probability": {"variance": 3e-06, "average": 0.998932, "min": 0.98941}, "location": {"width": 789, "top": 376, "height": 40, "left": 200}, "words": "的视力增加之后(每月一次给药后),在每三个月给药一次期间患者视力普遍出"}, {"probability": {"variance": 2e-06, "average": 0.99902, "min": 0.993466}, "location": {"width": 786, "top": 410, "height": 40, "left": 203}, "words": "现下降,在第12个月回到基线值,且在第24个月时大部分接受本品治疗的患者"}, {"probability": {"variance": 4e-06, "average": 0.998797, "min": 0.99056}, "location": {"width": 748, "top": 444, "height": 41, "left": 224}, "words": "82%)保持这一疗效。有些患者在一年假注射治疗后改为接受雷珠单抗治疗"}, {"probability": {"variance": 3e-06, "average": 0.998818, "min": 0.992195}, "location": {"width": 593, "top": 481, "height": 38, "left": 202}, "words": "其用药情况表明,早期使用雷珠单抗或许能更好地维持视力"}, {"probability": {"variance": 6.9e-05, "average": 0.996883, "min": 0.958455}, "location": {"width": 727, "top": 540, "height": 41, "left": 248}, "words": "在32位患者中开展了一项开放标签研究( PROTECT),随访期为9个月"}, {"probability": {"variance": 5e-05, "average": 0.996692, "min": 0.965213}, "location": {"width": 790, "top": 575, "height": 39, "left": 202}, "words": "评价了维替泊芬PDT和0.5mg雷珠单抗同一天给药的安全性。该研究的结果"}, {"probability": {"variance": 0.002532, "average": 0.986986, "min": 0.730837}, "location": {"width": 534, "top": 613, "height": 36, "left": 203}, "words": "表明,初始治疗后眼内炎症的发生率为6.3%(2/32)。"}, {"probability": {"variance": 0.009404, "average": 0.969655, "min": 0.455437}, "location": {"width": 720, "top": 670, "height": 40, "left": 248}, "words": "研究FVF3689g( SAILOR)为一项临床1b期、单盲、一年期多中心研究"}, {"probability": {"variance": 5.8e-05, "average": 0.996484, "min": 0.958411}, "location": {"width": 790, "top": 703, "height": 40, "left": 203}, "words": "在之前未经治疗的和经治疗的AMD继发CNV受试者中进行。主要研究目标是评"}, {"probability": {"variance": 0.000998, "average": 0.990935, "min": 0.821343}, "location": {"width": 789, "top": 738, "height": 40, "left": 203}, "words": "估接受12个月治疗的受试者中,眼部和非眼部严重不良事件的发生率。2378名患"}, {"probability": {"variance": 0.000193, "average": 0.99342, "min": 0.925877}, "location": {"width": 789, "top": 773, "height": 40, "left": 203}, "words": "者以1:1比例随机分配接受每月一次玻璃体内0.3mg或0.5mg本品治疗连续三个"}, {"probability": {"variance": 1e-06, "average": 0.999441, "min": 0.99657}, "location": {"width": 432, "top": 813, "height": 34, "left": 205}, "words": "月,之后按需再治疗,频率不超过每月一次"}, {"probability": {"variance": 6e-06, "average": 0.998933, "min": 0.987033}, "location": {"width": 744, "top": 868, "height": 39, "left": 249}, "words": "总体而言,两个剂量组之间没有观察到眼部和非眼部不良事件的发生率有不"}, {"probability": {"variance": 6.3e-05, "average": 0.995426, "min": 0.966446}, "location": {"width": 788, "top": 902, "height": 39, "left": 204}, "words": "平衡。统计学分析没有显示0.5mg组卒中发生率有增高的趋势,各自的卒中总体"}, {"probability": {"variance": 0.00055, "average": 0.989067, "min": 0.877874}, "location": {"width": 788, "top": 936, "height": 40, "left": 205}, "words": "发生率的95%置信区间较宽(0.3mg组为0.3%至1.3%,相比0.5mg组为0.7%至"}, {"probability": {"variance": 3.9e-05, "average": 0.997619, "min": 0.96817}, "location": {"width": 792, "top": 971, "height": 38, "left": 201}, "words": "20%)。两个给药组中发生卒中的患者数量均较小,不能得出结论(或排除)治"}, {"probability": {"variance": 0.000357, "average": 0.995061, "min": 0.88746}, "location": {"width": 775, "top": 1005, "height": 38, "left": 203}, "words": "疗组之间的卒中率确实有差异。卒中率的差异在具有已知卒中风险因子的患者"}, {"probability": {"variance": 0, "average": 0.999427, "min": 0.997645}, "location": {"width": 549, "top": 1042, "height": 36, "left": 205}, "words": "包括既往卒中病史或短暂性脑缺血发作史的患者中更大"}, {"probability": {"variance": 0, "average": 0.860052, "min": 0.860052}, "location": {"width": 94, "top": 1055, "height": 35, "left": 915}, "words": " HARMACE"}, {"probability": {"variance": 0.022421, "average": 0.947247, "min": 0.371449}, "location": {"width": 830, "top": 1088, "height": 60, "left": 219}, "words": "假注射对照操作为使用与本品玻璃体内注射相同的方式进行麻后使用无"}, {"probability": {"variance": 3.1e-05, "average": 0.997058, "min": 0.976544}, "location": {"width": 366, "top": 1140, "height": 32, "left": 207}, "words": "针头的注射器顶部压向结膜,并推针"}, {"probability": {"variance": 0, "average": 0.999654, "min": 0.998697}, "location": {"width": 233, "top": 1125, "height": 77, "left": 831}, "words": "有限公司"}, {"probability": {"variance": 0, "average": 0.804574, "min": 0.804574}, "location": {"width": 23, "top": 1145, "height": 27, "left": 1044}, "words": "8"}, {"probability": {"variance": 1e-06, "average": 0.998466, "min": 0.996619}, "location": {"width": 125, "top": 1215, "height": 29, "left": 213}, "words": "【药理毒理】"}, {"probability": {"variance": 0.057199, "average": 0.838873, "min": 0.361811}, "location": {"width": 227, "top": 1204, "height": 67, "left": 707}, "words": "德士(中国"}, {"probability": {"variance": 0.013423, "average": 0.95247, "min": 0.569215}, "location": {"width": 600, "top": 1256, "height": 46, "left": 249}, "words": "短尾猴双侧玻璃体腔内注射雷珠单抗0.25mg/眼至2.0m限"}, {"probability": {"variance": 0.008746, "average": 0.950159, "min": 0.721375}, "location": {"width": 185, "top": 1256, "height": 29, "left": 809}, "words": "眼的剂量范围,每"}, {"probability": {"variance": 0, "average": 0.999521, "min": 0.997962}, "location": {"width": 487, "top": 1293, "height": 35, "left": 205}, "words": "2周一次,持续26周,出现剂量依赖的眼部影响"}, {"probability": {"variance": 3e-06, "average": 0.999166, "min": 0.992478}, "location": {"width": 742, "top": 1349, "height": 40, "left": 252}, "words": "注射后2天,前房闪辉与细胞出现剂量依赖性增加并达到峰值。炎性反应的"}, {"probability": {"variance": 2e-06, "average": 0.999149, "min": 0.994187}, "location": {"width": 787, "top": 1383, "height": 40, "left": 207}, "words": "程度在随后注射治疗中或恢复期内通常减轻,但并未在所有病例中完全恢复。在"}, {"probability": {"variance": 1e-06, "average": 0.999363, "min": 0.996292}, "location": {"width": 789, "top": 1419, "height": 36, "left": 207}, "words": "眼后节,发生玻璃体浑浊,该症状同样有剂量依赖性倾向,且一般持续至治疗期"}, {"probability": {"variance": 2e-06, "average": 0.999077, "min": 0.992957}, "location": {"width": 788, "top": 1451, "height": 39, "left": 207}, "words": "结束。在26周的研究中,玻璃体炎症反应的严重程度随注射次数而增加。恢复"}, {"probability": {"variance": 7.6e-05, "average": 0.997277, "min": 0.948232}, "location": {"width": 789, "top": 1485, "height": 39, "left": 207}, "words": "期后观察到可逆的迹象。后节炎症的自然病程和持续时间显示这是免疫介导的抗"}], "language": 3}